Chandra Bhagat Pharma has scheduled a meeting of its Board of Directors for August 5, 2026, to consider a proposal for raising capital through the preferential allotment of equity shares, convertible warrants, or other instruments. The Board will also deliberate on increasing the company's authorized share capital and determining the date, time, and place for an Extraordinary General Meeting (EOGM) to obtain shareholder approval for these measures. This move signals the company's intent to strengthen its balance sheet or fund specific corporate initiatives, subject to regulatory compliances and shareholder consent.

The filing, submitted under Regulation 29(1)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, outlines the key agenda items for the upcoming session. In addition to the fund-raising proposal and capital increase, the Board will address any other business incidental and ancillary to the primary agenda, with the permission of the chair. The final terms of the preferential issue, including pricing and allocation, will be determined during this meeting before being presented to shareholders.

In accordance with the Code of Conduct for prevention of insider trading, framed under the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in the company's securities is closed. This restriction applies to all connected persons, officers, designated employees, directors, and their immediate relatives from July 30, 2026, until the end of 48 hours from the conclusion of the Board Meeting. This measure ensures fair disclosure and prevents insider trading ahead of material announcements.

The preferential allotment route allows the company to raise funds from specific investors without a public issue, often used for strategic partnerships or quick capital infusion. The inclusion of convertible warrants as a potential instrument suggests flexibility in structuring the deal to meet investor requirements while potentially deferring immediate equity dilution. The subsequent EOGM is a mandatory step to ensure that existing shareholders have the opportunity to approve the issuance of new securities, which could impact their ownership percentage.

What the Numbers Show

While specific financial figures regarding the amount to be raised or the valuation of the shares are not disclosed in this preliminary intimation, the decision to increase authorized share capital indicates a strategic preparation for future growth or restructuring. The dual focus on capital raising and authorized capital expansion suggests that Chandra Bhagat Pharma is positioning itself for significant operational changes or investments that require both immediate funding and long-term equity capacity. Investors will need to monitor the EOGM notice for detailed terms, including the issue price and the identity of potential allottees, which will provide clearer insights into the company's financial strategy.

Chandra Bhagat Pharma Limited reported a 255% increase in net profit to ₹304.61 lakh for the financial year ended March 31, 2026, compared to ₹85.78 lakh in the previous year. Revenue from operations surged 30.9% to ₹11,627.17 lakh from ₹8,880.54 lakh in FY25. The board approved the audited financial results for the half year and year ended March 31, 2026, at a meeting held on May 25, 2026.

Financial Performance

The company's earnings per share (EPS) for the year stood at ₹4.04, up from ₹1.14 in the prior year. Total income from operations rose to ₹11,962.50 lakh for FY26, compared to ₹9,223.91 lakh in FY25. Expenses for the year totaled ₹11,552.01 lakh, an increase from ₹9,107.37 lakh in the previous year.

Balance Sheet and Cash Flows

The company's reserves and surplus increased to ₹2,558.14 lakh as of March 31, 2026, from ₹2,242.40 lakh a year earlier. Cash and bank balances improved significantly to ₹311.06 lakh from ₹66.51 lakh. Trade receivables rose to ₹5,461.70 lakh from ₹3,594.55 lakh, while short-term borrowings decreased to ₹1,393.92 lakh from ₹1,857.65 lakh.

Net cash generated from operating activities was ₹923.57 lakh, a turnaround from a net outflow of ₹570.89 lakh in the previous year. The company utilized ₹43.46 lakh in investing activities and ₹635.57 lakh in financing activities.

Auditor and Compliance

Statutory Auditors M/S A Y & Company issued an unmodified opinion on the audited financial results. The report confirms compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The trading window for directors and designated personnel will open 48 hours after the announcement of the financial results.